| Name | Title | Contact Details |
|---|
Weve run the gambit on virtually everything you can do with an automobile. From donuts at Tire Slayer Studios to gravity-defying stunts on the streets of Las Vegas, weve earned our stripes on the automotive front lines, the pits, and the winners podium. Its a sense of pride and passion that allows us to continue to push the boundaries that make us who we are. At our core, we are enthusiasts just like our customers. We connect with our fans in a way most brands cant imagine. Because at one time, we, too, were just enthusiasts pursuing our passion for automotive culture and watching our motorsport heroes from the grandstands.
The Ninety Nine Restaurant & Pub is headquartered in Woburn, Massachusetts, and has earned a strong reputation as a friendly, comfortable place to gather and enjoy great food and great drink at a terrific price. With the establishment of the Ninety Nine Restaurant & Pub in 1952, founder Charlie Doe created an entirely new niche in the New England hospitality industry – the casual restaurant – long before the appearance of others. The Ninety Nine Restaurant & Pub continues to prosper and grow. The Ninety Nine updates and refines its menu on an ongoing basis to provide guests with fresh new options, yet continues to offer great food and great drink at a terrific price. This philosophy began when the company was founded, and is still maintained today. The culture at the Ninety Nine Restaurant & Pub was instilled by Charlie Doe long before a mission statement was ever written down on paper. But the proclamation means that guests, team members, community and stakeholders are treated with respect. For guests, it means they have a friendly, comfortable place to gather and enjoy great food and great drink at a terrific price. The Ninety Nine is proud to serve more than 20 million customers a year in over 105 restaurants throughout the Northeast. For team members it translates into accommodating work schedules, generous benefits, including 401(k) plans and health, life and dental insurance (for hourly and part-time team members as well); and plentiful rewards for top performers.
Established in 1987, Flying Star Cafe is a dedicated partner of the Albuquerque community, making us one of the largest and most popular restaurant companies in New Mexico. We serve award-winning fresh foods, baked goods, and fine Arabica coffee beans in an upbeat, unique environment, complemented by what we call "Stellar Service" from our employees, to enhance the overall guest experience. We source and serve top quality products, because at the core of our cooking and baking is a commitment to feeding our guests responsibly as well as deliciously. This commitment is found behind the counter as well as in the kitchen and is the primary focus of our in-depth training program and company growth – we are exceptional and so is our product! We offer a fun place to work, where youll find friendly people, opportunities to grow within our company, and great benefits. Find out more: http://www.flyingstarcafe.com/careers.htm.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.